Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

PSB and Farminerva collaborate to develop diagnostics and new therapeutic in peptide based biopharmaceuticals

14.11.2006
Fondazione Parco Biomedico San Raffaele and a new Lazio based biotechnology firm, Farminerva S.r.l. have signed an agreement to collaborate on the development of novel biopharmaceutical peptide based diagnostics and therapeutics.

The collaboration will involve the permanent presence of a Farminerva S.r.l. section on the science park, and will join two other biotechnology companies present there (LayLine Genomics and BioLab). Effort will be dedicated to accelerating domestic and international partnerships to in-license or co-develop new intellectual property with the aim to move the development as far as possible up the biomedical product value chain, prior to out-licensing for significant value creations.

Fondazione Parco Biomedico San Raffaele (PSB)

Located approximately 15 km south of Rome in a natural reserve, the science park was created by the Banca di Roma, the Chamber of Commerce of Rome, and the Fondazione San Raffaele Monte Tabor in response to the recognised need to have a biomedical research centre in the Lazio region. Opened in 2002, the park is now home to 3 companies and 9 research groups from Universities and centres working in: Stem cells, Oncology, leukaemia and Immunology; Molecular cardiology; Skeletal regeneration; Cell therapy and tissue engineering; Muscular dystrophies; Biomedical quality control; Neurological Disorders and Diabetes. The infrastructure permits the development of concept to preclinical development based on the state-of-the-art facilities including a animal facility encompassing conventional and SPF small animals and a large animal surgery unit.

... more about:
»Development »Farminerva »therapeutic

Farminerva

Farminerva is a private company, founded in 2006, focused on research activities to reach new advanced solutions in biomedical sector. These objectives are developed by a strong cooperation with academic and institutional centres, as the Fondazione Parco Biomedico San Raffaele and CRISC of the Rome University, where Farminerva sponsors the execution of all preclinical and clinical studies requested by local regulatory authorities to obtain marketing license.

This collaboration defines a platform which promotes and coordinates research projects from preclinical to clinical phases to improve specific knowledge in two particular field: the first one concerns new products useful in early diagnosis of orthopaedic, cardiovascular, bone tissue inflammatory and/or infective based diseases, diabetic and oncological diseases. Further effort will be targeted on developing drugs for treatment of infective, diabetic and oncological diseases.

The other one aims to discovery new therapeutic indication of generic drugs to treat neurological, psychiatric and abuse disorders (second/other medical use), through the participation of CNR IASI researchers which perform advanced statistical analysis on large database (1/3 million of subjects) to identify co-morbidity data of relevant clinic interest.

About 50 free lance professionals work in Farminerva projects to ensure high quality level in management and monitoring activities and significantly shorter time to achieve the marketing phase.

Jonathan Dando | alfa
Further information:
http://www.scienceparkrome.org

Further reports about: Development Farminerva therapeutic

More articles from Life Sciences:

nachricht The birth of a new protein
20.10.2017 | University of Arizona

nachricht Building New Moss Factories
20.10.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

Metallic nanoparticles will help to determine the percentage of volatile compounds

20.10.2017 | Materials Sciences

Shallow soils promote savannas in South America

20.10.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>